Loading...
XNAS
AVXL
Market cap970mUSD
Jul 29, Last price  
11.36USD
1D
-1.82%
1Q
19.58%
Jan 2017
186.87%
IPO
37.86%
Name

Anavex Life Sciences Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
11.28%
Rev. gr., 5y
%
Revenues
0k
Net income
-43m
L-9.48%
-91,625-25,532-1,579,993-5,351,269-5,499,419-8,783,037-7,307,147-8,301,705-3,700,046-11,368,353-12,108,130-14,736,698-13,460,405-17,453,409-26,294,979-26,280,470-37,908,634-47,977,919-47,505,000-43,002,000
CFO
-31m
L+10.89%
-61,072-32,428-325,250-2,474,053-2,794,655-4,593,588-3,801,479-1,692,940-777,573-2,659,379-4,227,006-9,236,823-9,017,231-12,582,406-18,527,117-21,287,046-30,383,674-24,237,864-27,785,000-30,812,000
Earnings
Aug 04, 2025

Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
IPO date
Apr 13, 2006
Employees
38
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
52,877
55,756
50,986
Unusual Expense (Income)
NOPBT
(52,877)
(55,756)
(50,986)
NOPBT Margin
Operating Taxes
7
358
Tax Rate
NOPAT
(52,877)
(55,763)
(51,344)
Net income
(43,002)
-9.48%
(47,505)
-0.99%
(47,978)
26.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,284
27,875
20,985
BB yield
-2.38%
-5.33%
-2.64%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
4,835
4,269
Net debt
(132,187)
(151,024)
(149,158)
Cash flow
Cash from operating activities
(30,812)
(27,785)
(24,238)
CAPEX
Cash from investing activities
Cash from financing activities
11,975
29,651
21,288
FCF
(52,877)
(55,763)
(51,344)
Balance
Cash
132,187
151,024
149,158
Long term investments
Excess cash
132,187
151,024
149,158
Stockholders' equity
(335,986)
(292,987)
(245,486)
Invested Capital
456,249
434,839
387,977
ROIC
ROCE
EV
Common stock shares outstanding
83,468
79,788
76,910
Price
5.68
-13.28%
6.55
-36.53%
10.32
-42.51%
Market cap
474,099
-9.28%
522,609
-34.16%
793,711
-36.65%
EV
341,912
371,585
644,553
EBITDA
(52,877)
(55,756)
(50,986)
EV/EBITDA
Interest
964
947
Interest/NOPBT